Zynaxis regulatory update

ZNXS received two U.S. patents for its drug and vaccine delivery technologies. Patent No. 5,480,901 covers the use of ZNXS’s Zyn-Linker molecules to deliver drugs that reduce cellular adhesions. Zyn-Linkers incorporating anti-adhesive drugs have been shown in animal models to reduce the ability of tumors to adhere to surrounding normal tissues and also appear to reduce the capacity of the shed tumor cells to attach and form new tumors, ZNXS said. ...